Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Licenses Evrogen's Fluorescent Proteins

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis Bioresearch today announced a non-exclusive agreement giving it access to Evrogen's fluorescent proteins.

The deal allows Paris-based Cellectis to incorporate the proteins into its own products, expanding its portfolio of genome engineering tools.

Financial and other terms were not disclosed.

Based in Moscow, Evrogen develops technologies for molecular and cell biology.

In a statement, Luc Selig, sales and marketing director for Cellectis, said that the integration matrix, which allows researchers to express a gene of interest, is a "key component" of the company's kits. The deal with Evrogen extends the choice of promoters and tags in these matrices, and as a result Cellectis can offer its clients "a full range of methods to achieve single-phase developments, thus saving valuable time during experiments."

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.